R5 to X4 switch of the predominant HIV-1 population in cellular reservoirs during effective highly active antiretroviral therapy

Journal of Acquired Immune Deficiency Syndromes

Volumn 38, Issue 4, 2005, Pages 382-392

  Delobel, Pierre ^a   Sandres Sauné, Karine ^a   Cazabat, Michelle ^a   Pasquier, Christophe ^a   Marchou, Bruno ^a   Massip, Patrice ^a   Izopet, Jacques ^a  

^a CHU PURPAN   (France)

Author keywords

CCR5; CXCR4; Highly active antiretroviral therapy; HIV reservoirs; HIV 1

Indexed keywords

CHEMOKINE RECEPTOR CCR5; CHEMOKINE RECEPTOR CXCR4; LAMIVUDINE; RNA DIRECTED DNA POLYMERASE INHIBITOR; STAVUDINE; ZIDOVUDINE;

ARTICLE; CLINICAL ARTICLE; DISEASE COURSE; ENVELOPE GENE; GENETIC ANALYSIS; GENOTYPE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; NUCLEOTIDE SEQUENCE; PATHOGENESIS; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL;

ACQUIRED IMMUNODEFICIENCY SYNDROME; ADULT; AMINO ACID SEQUENCE; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CD4 LYMPHOCYTE COUNT; CD4-POSITIVE T-LYMPHOCYTES; DISEASE RESERVOIRS; FEMALE; GENE PRODUCTS, ENV; GENES, ENV; GENOTYPE; HIV-1; HUMANS; MALE; MIDDLE AGED; MOLECULAR SEQUENCE DATA; RNA, VIRAL; VARIATION (GENETICS); VIRAL LOAD;

EID: 15044339793     PISSN: 15254135     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.qai.0000152835.17747.47     Document Type: Article

References (50)

1. Berger EA, Murphy PM, Farber JM. Chemokine receptors as HIV-1 coreceptors: roles in viral entry, tropism, and disease. Annu Rev Immunol. 1999;17:657-700.
2. Berger EA, Doms RW, Fenyo EM, et al. A new classification for HIV-1. Nature. 1998;391:240.
3. Tersmette M, de Goede RE, Al BJ, et al. Differential syncytium-inducing capacity of human immunodeficiency virus isolates: frequent detection of syncytium-inducing isolates in patients with acquired immunodeficiency syndrome (AIDS) and AIDS-related complex. J Virol 1988;62:2026-2032.
4. Schuitemaker H, Koot M, Kootstra NA, et al. Biological phenotype of human immunodeficiency virus type 1 clones at different stages of infection: progression of diseases is associated with a shift from monocytotropic to T-cell tropic virus population. J Virol. 1992;66:1354-1360.
5. Koot M, Keet IP, Vos AH, et al. Prognostic value of HIV-1 syncytium-inducing phenotype for rate of CD4+ cell depletion and progression to AIDS. Ann Intern Med. 1993;118:681-688.
6. Richman DD, Bozzette SA. The impact of the syncytium-inducing phenotype of human immunodeficiency virus on disease progression. J Infect Dis. 1994;169:968-974.
7. Wong JK, Hezareh M, Gunthard HF, et al. Recovery of replication competent HIV despite prolonged suppression of plasma viremia. Science. 1997;278:1291-1295.
8. Finzi D, Hermankova M, Pierson T, el al. Identification of a reservoir for HIV-1 in patients on highly active antiretroviral therapy. Science. 1997; 278:1295-1300.
9. Finzi D, Blankson J, Siliciano JD, et al. Latent infection of CD4+ T cells provides a mechanism for lifelong persistence of HIV-1, even in patients on effective combination therapy. Nat Med. 1999;5:512-517.
10. Dornadula G, Zhang H, VanUitert B, et al. Residual HIV-1 RNA in blood plasma of patients taking suppressive highly active antiretroviral therapy. JAMA. 1999;282:1627-1632.
11. Furtado MR, Callaway DS, Phair JP, et al. Persistence of HIV-1 transcription in peripheral-blood mononuclear cells in patients receiving potent antiretroviral therapy. N Engl J Med. 1999;340:1614-1622.
12. Lafeuillade A. Chollet L, Hittinger G, et al. Residual human immunodeficiency virus type 1 RNA in lymphoid tissue of patients with sustained plasma RNA of <200 copies/mL. J Infect Dis. 1998;177:235-238.
13. Natarajan V, Bosche M, Metcalf JA. et al. HIV-1 replication in patients with undetectable plasma virus receiving HAART. Lancet. 1999;353: 119-120.
14. Ramratnam B, Mittler JE, Zhang L, et al. The decay of the latent reservoir of replication-competent HIV-1 is inversely correlated with the extent of residual replication during prolonged anti-retroviral therapy. Nat Med. 2000;6:82-85.
15. Gunthard HF, Frost SD, Leigh-Brown AJ, et al. Evolution of envelope sequences of human immunodeficiency virus type 1 in cellular reservoirs in the setting of potent antiviral therapy. J Virol. 1999;73:9404-9412.
16. Martinez MA, Cabana M, Ibanez A, et al. Human immunodeficiency virus type 1 genetic evolution in patients with prolonged suppression of plasma viremia. Virology. 1999;256:180-187.
17. Izopet J, Cazabat M, Pasquier C, et al. Evolution of total and integrated HIV-1 DNA and change in DNA sequences in patients with sustained plasma virus suppression. Virology. 2002;302:393-404.
18. Blaak H, van't Wout AB, Brouwer M, et al. In vivo HIV-1 infection of CD45RA+ CD4+ T cells is established primarily by syncytium-inducing variants and correlates with the rate of CD4+ T cell decline. Proc Natl Acad Sci USA. 2000;97:1269-1274.
19. Ostrowski MA, Chun TW. Justement SJ, et al. Both memory and CD45RA +/CD62L+ naive CD4+ T cells are infected in human immunodeficiency virus type-1 infected individuals. J Virol. 1999;73:6430-6435.
20. Bleui CC, Wu L, Hoxie JA, et al. The HIV coreceptors CXCR4 and CCR5 are differentially expressed and regulated on human T lymphocytes. Proc Natl Acad Sci USA. 1997;94:1925-1930.
21. Taylor JR Jr, Kimbrell KC, Scoggins R, et al. Expression and function of chemokine receptors on human thymocytes: implications for infection by human immunodeficiency virus type 1. J Virol. 2001;75:8752-8760.
22. Autran B, Carcelain G, Li TS, et al. Positive effects of combined antiretroviral therapy on CD4+ T cell homeostasis and function in advanced HIV disease. Science. 1997;277:112-116.
23. Sempowski GD, Haynes BF. Immune reconstitution in patients with HIV infection. Annu Rev Med. 2002;53:269-284.
24. Xiao L, Owen SM, Goldman I, et al. CCR5 coreceptor usage of non-syncytium-inducing primary HIV-1 is independent of phylogenetically distinct global HIV-1 isolates: delineation of consensus motif in the V3 domain that predicts CCR5 usage. Virology. 1998;240:83-92.
25. Hung CS, Vander Heyden N, Ratner L. Analysis of the critical domain of V3 loop of human immunodeficiency virus type 1 gp120 involved in CCR5 utilization. J Virol. 1999;73:8216-8226.
26. DeJong JJ, De Ronde A, Keulen W. et al. Minimal requirements for the human immunodeficiency virus type 1 V3 domain to support the syncytium-inducing phenotype: analysis by single amino-acid substitution. J Virol. 1992;66:6777-6780.
27. Fouchier RA, Groenink M, Kootstra NA, et al. Phenotype-associated sequence variation in the third variable domain of the human-immunodeficiency virus type 1 gp120 molecule. J Virol. 1992;66:3183-3187.
28. Briggs DR, Tuttle DL, Sleasman JW, et al. Envelope V3 amino acid sequence predicts HIV-1 phenotype (coreceptor usage and tropism for macrophage). AIDS. 2000;14:2937-2939.
29. Jensen MA, Li FS, van't-Wout AB, et al. Improved coreceptor usage prediction and genotypic monitoring of R5-to-X4 transition by motif analysis of human immunodeficiency virus type 1 env V3 loop sequences. J Virol. 2003;77:13376-13388.
30. Li Y, Rey-Cuille MA, Hu SL. N-linked glycosylation in the V3 region of HIV type 1 surface antigen modulates coreceptor usage in viral infection. AIDS Res Hum Retroviruses. 2001;17:1473-1479.
31. Pollakis G, Kang S, Kliphuis A, et al. N-linked glycosylation of the HIV type-1 gp120 envelope glycoprotein as a major determinant of CCR5 and CXCR4 coreceptor utilization. J Biol Chem. 2001;276:13433-13441.
32. Johnston ER, Zijenah LS, Mutetwa S, et al. High frequency of syncytium-inducing and CXCR4-tropic viruses among human immunodeficiency virus type 1 subtype C-infected patients receiving antiretroviral treatment. J Virol. 2003;77:7682-7688.
33. Cecilia D, Kulkarn SS, Tripathy SP, et al. Absence of coreceptor switch with disease progression in human immunodeficiency virus infections in India. Virology. 2000;271:253-258.
34. Ping LH, Nelson JA, Hoffman IF, et al. Characterization of V3 sequence heterogeneity in subtype C human immunodeficiency virus type 1 isolates from Malawi: underrepresentation of X4 variants. J Virol. 1999;73:6271-6281.
35. Delforge ML, Liesnard C, Debaisieux L, et al. In vivo inhibition of syncytium-inducing variants of HIV-1 in patients treated with didanosine. AIDS. 1995;9:89-90.
36. Ercoli L, Sarmati L, Nicastri E, et al. HIV phenotype switching during antiretroviral therapy: emergence of saquinavir-resistant strains with less cytopathogenicity. AIDS. 1997;11:1211-1217.
37. Mckinney RE Jr, Johnson GM, Stanley K, et al. A randomized study of combined zidovudine-lamivudine versus didanosine monotherapy in children with symptomatic therapy-naive HIV-1 infection. The Pediatric AIDS Clinical Trial Group Protocol 300 Study Team. J Pediatr. 1998;133: 500-508.
38. Equils O, Garratty E, Wei LS, et al. Recovery of replication-competent virus from CD4 T cell reservoirs and change in coreceptor use in human immunodeficiency virus type 1-infected children responding to highly active antiretroviral therapy. J Infect Dis. 2000;182:751-757.
39. Philpott S, Weiser B, Anastos K, et al. Preferential suppression of CXCR4-specific strains of HIV-1 by antiretroviral therapy. J Clin Invest. 2001;107:431-438.
40. Skrabal K, Trouplin V, Labrosse B, et al. Impact of antiretroviral therapy on the tropism of HIV-1 plasma virus populations. AIDS. 2003;17:809-814.
41. Pierson T, Hoffman TL, Blankson J, et al. Characterization of chemokine receptor utilization of viruses in the latent reservoir for human immunodeficiency virus type 1. J Virol. 2000;74:7824-7833.
42. van Rij RP, Visser JA, van Praag RM, et al. Both R5 and X4 human immunodeficiency virus type 1 variants persist during prolonged therapy with five antiretroviral drugs. J Virol. 2002;76:3054-3058.
43. Shankarappa R, Margolick JB, Gange SJ. Consistent viral evolutionary changes associated with the progression of human immunodeficiency virus type 1 infection. J Virol. 1999;73:10489-10502.
44. Brenchley JM, Hill BJ, Ambrozak DR, et al. T-cell subsets that harbor human immunodeficiency virus (HIV) in vivo: implications for HIV pathogenesis. J Virol. 2004;78:1160-1168.
45. Schmitt N, Chêne L, Boutolleau D, et al. Positive regulation of CXCR4 expression and signaling by interleukin-7 in CD4+ mature thymocytes correlates with their capacity to favor human immunodeficiency X4 virus replication. J Virol. 2003;77:5784-5793.
46. Llano A, Barretina J, Gutierrez A, et al. Interleukin-7 in plasma correlates with CD4+ T-cell depletion and may be associated with emergence of Syncytium-inducing variants in human immunodeficiency virus type-1 positive individuals. J Virol. 2001;75:10319-10325.
47. Nicastri E, Sarmati L, d'Ettorre G, et al. Replication capacity, biological phenotype, and drug resistance of HIV strains isolated from patients failing antiretroviral therapy. J Med Virol. 2003;69:1-6.
48. Sallusto F, Geginat J, Lanzavecchia A. Central memory and effector memory T cell subsets: function, generation, and maintenance. Annu Rev Immunol. 2004;22:745-763.
49. Brumme ZL. Dong WWY, Yip B, et al. Clinical and immunological impact of HIV envelope V3 sequence variation after starting initial triple antiretroviral therapy. AIDS. 2004;18:F1-F9.
50. Correa R, Munoz-Fernandez MA. Viral phenotype affects the thymic production of new T cells in HIV-infected children. AIDS. 2001;15:1959-1963.